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Abstract In mice, three pluripotent stem cell lines have
been established from different stage of developing
embryo, which are embryonic stem (ES) cell, post-
implantation epiblast stem cell (EpiSC), and embryonic
germ (EG) cell. ES cell and EG cell share many common
features including factor requirement, colony morphology,
and gene expression pattern. On the other hand, EpiSC
needs different external signal inputs, exhibits flattened
colony morphology, and a different set of gene expression
patterns. In addition, the germ line competency of EpiSCs
is still unclear. To distinguish the differences between
them, they are defined by the words ‘‘naı¨ve’’ and ‘‘primed’’
pluripotent cells, respectively. This article introduces how
pluripotent stem cell lines are established in culture, and
how much those cells in vitro are similar or relevant to
their in vivo origin and the knowledge about transcription
factors to support this state.
Keywords EG cells  Epiblast  EpiSC  ES cell 
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Introduction
Pluripotency is the word that represents the cell state that
gives rise to all three germ layers: ectoderm, mesoderm,
and endoderm. Pluripotent cells only exist at the early
starting point of our lifetime. Importantly, this pluripotent
cell state is a transient one, which can be observed in
mammalian development. We are now capable of captur-
ing some of these pluripotent cells in culture. According to
the recent progress of the imaging tools as well as embryo
culture, we can monitor peri-implantation development
in vitro relatively easily and also genetics allows us to
examine the gene function in a stage- or tissue-specific
manner. Thanks to these techniques, our understanding
about how the mammalian embryo develops from fertilized
egg is deepened, as is our knowledge about pluripotent
stem cell in culture, especially for mice. In this article, I
describe pluripotency in vivo and in vitro and their rela-
tionship together with the external signals and gene func-
tions which support their status.
Pluripotent cells in mouse development
How totipotent cells become pluripotent cells
The fertilized egg of mice is a totipotent cell in definition
because this unique cell can become every type of cell,
including extraembryonic tissues such as placenta or yolk
sac. After fertilization, the cell divides without increasing
the total embryo size, a process called cleavage, and cells
of the embryo around this stage look identical until the
eight-cell stage. At the eight-cell stage, compaction occurs,
and cell–cell interaction causes polarization. The cells
located on the outer surface of the embryo around the
8–16-cell stage embryo become trophectoderm, which
contributes to the future placenta [1, 2], and this is the first
extraembryonic lineage determined in embryonic devel-
opment. As the embryo develops, inside cells locate on the
inside wall of the trophectoderm layer as an aggregate
called inner cell mass (ICM). ICM at this stage consists of
a mixed population of future epiblast cells (which
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contribute to the embryo) and extraembryonic endoderm
cells, which is the second lineage segregated from the
embryonic lineage [3]. Just before implantation, the cells at
the surface of the blastocoel commit to their fate of
primitive endoderm (PrEn) as a morphologically visible
single layer (Fig. 1a in red color) [3]. The mechanism for
cell sorting is not well understood, but there is a tendency
for cells destined to become primitive endoderm travel
through the ICM toward the blastocoel in an actin-depen-
dent manner [4, 5]. Epiblast cells after the PrEn cells
segregated (Fig. 1a, blue color) are the pluripotent cells
because all of the somatic cells are derived from these
cells.
Epiblast cells after implantation
After implantation, apolarized ICM cells continue to pro-
liferate and line up as one sheet of epithelial cells which
have an apical-basal polarity in a cup-shaped structure
called an egg cylinder in rodents, disc in other mammals.
The polarized epiblast cells are attached to the basement
membrane produced by surrounding visceral endoderm
cells (Fig. 1b). Recent study suggests that apical constric-
tion of basement membrane-anchored ICM cells causes
cavity formation at the apical surface of ICM cells [6].
Another study from embryoid body-based cavity formation
analysis [7, 8] shows that cells that are not incorporated
into the epithelial layer undergo apoptosis. These mecha-
nisms both contribute to make proamniotic cavity.
Epiblast cells collected from embryonic day (E)6 and E7
embryo do not colonize the embryo when injected into the
blastocyst stage [9], but these cells were shown to make all
three germ layer derivatives when ectopically introduced
into another host animals [10, 11]. The cells constituting
postimplantation epiblast have been shown to contribute
efficiently to PGCs in vitro when cultured in high doses of
bone morphogenetic protein (BMP). These studies show
that post-implantation epiblast cells still harbor pluripo-
tency that can give rise to any types of the cells, including
germ cells [12].
Unipotent cell converts to pluripotent cell in vivo
Another type of pluripotency-related cell observed in the
developing embryo is the germ cell. Germ cells are uni-
potent cells that normally give rise to sperm or egg. In
developing mice, primordial germ cells (PGCs) firstly
emerge around the pre-gastrulation stage as a few Blimp1
Fig. 1 Pluripotent cells in culture and their origin in embryos a E4.5
mouse embryo. a’ Mouse embryonic stem cell cultured in 2i and LIF
on a gelatin-coated plate. b E5.5 mouse embryo. b’ Mouse EpiSC
cultured in activin and bFGF on fibronectin-coated plate. c E8.5
mouse embryo. c’ Mouse EG cells cultured in 2i and LIF with feeder
cells. Cells in blue in (a, b) show the pluripotent epiblast and in
c show the location of PGC cells at this stage. Red cells in (a, b) are
extra-embryonic endoderm cells. Scale bar in a, b is 50 lm and a’–c’
is 100 lm
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expressing alkaline phosphatase (AP)-positive cells in the
posterior proximal epiblast [13, 14]. These cells proliferate
and repress the somatic gene programs during gastrulation
[15]. They form AP-positive cell clusters at the bottom of
the allantois. Then PGCs migrate along the hindgut and
colonize the aorta-gonad-mesonephros (AGM) region until
around E12.5 to become mature germ cells. Though PGC
itself in vivo is not pluripotent but uni-potent, these PGCs
are the origin of embryonal carcinoma (EC), which
is sometimes observed in 129 mice strains [16]. EC tumors
contain three germ layer derivatives, so PGC is not nor-
mally pluripotent, but rarely, it converts to pluripotent cell
state in vivo.
Pluripotency in culture
Pluripotent cells from peri-implantation-stage epiblast
As introduced above, there are transient pluripotent cell
states during development, and nowadays we can establish
pluripotent stem cell lines from these different stages of the
developing embryo. Mouse embryonic stem (ES) cells
(Fig. 1a’) are established from pre-implantation stage
ICMs (E3.5–E4.5), post-implantation epiblast stem cells
(EpiSCs) (Fig. 1b’) are established from peri-gastrulating
embryo (E5.5–E8.0), and we also can establish pluripotent
stem cells in vitro from PGCs [from E8.5 (Fig. 1c) to
E12.5], called embryonic germ (EG) cells (Fig. 1c’) [17,
18] (Table 1). Interestingly, ES and EG cells have different
origins in terms of developmental stage, but they share
common features including culture condition, growth fac-
tor requirement and chimera formation ability.
Historically, in vivo pluripotency was first shown in EC
cells [19]. When these cells are ectopically transplanted
into a recipient animal, they give rise to tumors that consist
of three germ layer-derived cells. EC cells were then
shown to have the ability to contribute to host embryo
development to make a chimeric animal when injected into
blastocyst-stage embryos [20], but only a few EC cell lines
have this ability. Reliable contribution to chimera is one of
the special features of mouse ES cells, different from EC
cells, focused on in this article.
mES cells were first established from the ICM of the
blastocyst-stage embryo in 1981 [21, 22]. mES cells
injected into a host embryo can contribute to every somatic
lineage including germ cells in accordance with the host
embryo development. Contrary to the features that EC cells
are different from line to line, ES cells are more similar to
each other in terms of morphology, culture condition, and
ability for making chimeric animal. Since then, researchers
are in pursuit to understand why these cells can be kept
undifferentiated in vitro. ES cells are derived from the
early embryo, so can be used for understanding early
mammalian development as an in vitro model, and also
human ES cells can be expected to be used for clinical
applications in so-called ‘‘regenerative medicine.’’ Another
useful role of ES cells is making transgenic animals.
Because ES cells can contribute to every cell type
including germ cells, once the transgenic ES cells are
established by homologous recombination of the gene of
interest, mating the chimeric animal to a wild type allows
establishment of new mouse lines that can be used for gene
function analysis.
Pluripotent cells from post-implantation epiblast
EpiSCs has been reported in 2007 from mouse post-
implantation-stage embryo [23, 24] and rat post-implanta-
tion-stage embryo [23]. This pluripotent cell line is estab-
lished from post-implantation-stage epiblast, so it is called
post-implantation epiblast stem cell (EpiSC) to distinguish
from ES cells established from pre-implantation-stage
epiblast. EpiSC lines have some similarities to human ES
cells that are established from human blastocysts [25]. For
example, growth factor requirements for these cells are
basic fibroblast growth factor (bFgf) and activin instead of
leukemia inhibitory factor (LIF). Their morphology is a flat
Table 1 Features of naı¨ve and primed cells
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two-dimensional colony, but mES cells are dome-shaped
and three-dimensional. Pluripotency of these cells is shown
by teratoma forming ability when ectopically transplanted
into immune-deficient host animals, but when injected into
blastocysts, mEpiSCs very rarely contribute to a chimeric
animal [23]. Recently, E-cadherin overexpressing EpiSC
was reported to contribute to chimeras by blastocyst
injection, but the underlying mechanism is still unknown
[26], and no germ line contribution of these cells was
observed. Another group injected EpiSC into ex vivo cul-
tured egg cylinder-stage embryos of the equivalent devel-
opmental stage to EpiSC origin. They reported that injected
EpiSC into E7.5 embryo incorporate into the host and
contribute to chimeric tissue including AP-positive, puta-
tive germ cells [27]. In human ES cell differentiation cul-
ture, there are some reports that hES cells differentiate into
VASA-positive pre-meiotic germ cells in three-dimen-
sional culture, though it is still controversial whether these
types of stem cells have the potency to become germ cells
[28–30].
Another similarity is that both human ESC and mouse
EpiSC are fragile when dissociated at the single cell level;
they activate the pathway to apoptotic cell death triggered
by blebbing. When Rho-associated coiled-coil containing
protein kinase (ROCK) inhibitor is added to block this, cell
death can be avoidable [31, 32].
Pluripotent cells from PGC
EG cells were first established from PGCs of E8.5 and
E12.5 in the presence of stem cell factor (SCF), LIF, and
bFGF [17], and it has been confirmed that they are germ
line-competent cell lines [33, 34]. As described above,
PGC in vivo is a uni-potent cell that only makes sperm or
egg, so the conversion of PGC to EG cell is an in vitro
reprogramming process. Once they become EG cells, they
are very similar to ES cells in every aspect. For example,
they can grow in serum and LIF or 2i condition (a recently
establish culture condition for ES cells containing two
kinase inhibitors [35], described later in this article), and
their gene expression profiles and DNA methylation status
are similar to those of ES cells [36].
Naı¨ve and primed pluripotency
Because of obvious differences between established plu-
ripotent stem cells, the pluripotent state of EpiSC is defined
as ‘‘primed pluripotency’’ to distinguish from mES and
mEG cells’ ‘‘naı¨ve pluripotency’’ [37]. Naı¨ve and primed
states have some more, different features (listed in
Table 1). One example is that female naı¨ve mES cells have
both active X chromosomes (XaXa), but primed female
stem cells have only one active chromosome and the other
is inactivated (XaXi). This might represent the difference
of the developmental stage from which each type of cells is
established.
Reprogrammed pluripotency
In 2006, Takahashi and Yamanaka found a new technology
to induce pluripotent stem cells from terminally differen-
tiated somatic cells by the specific combination of trans-
genes (Oct3/4, Sox2, Klf4, and cMyc) [38]. The finding
was striking in showing that the key transcription fac-
tor(s) are sufficient to change the fate into totally different
types of cells. These reprogrammed cells are named
induced pluripotent stem (iPS) cells. When these Yama-
naka factors are introduced into mouse embryonic fibro-
blasts, they form the dome-shaped colony that can be
maintained similar to ES cells and these reprogrammed
cells can colonize a host animal when injected into the
blastocyst-stage embryo to make a chimeric mouse.
Importantly, germ line competency of the iPS-derived
chimeras were confirmed in 2007 [39–41]. In 2011, Hay-
ashi et al. [42] succeeded in inducing mouse PGC-like cells
from male ES cells as well as male iPS cells, which can be
a functional sperm when introduced into seminiferous
tubules of the host male. They also succeeded in making
functional female PGC-like cells from both ES cells and
iPS cells [43]. These female PGC-like cells can become
mature oocytes when transplanted into host animals and
make offspring by in vitro fertilization.
iPS technology is applied to reprogram human somatic
cells as well. This technology is really useful because we
can utilize patient-derived iPS as a disease model to
uncover the mechanism of disease development and drug
discovery, as well as a tool to understand human devel-
opment and a potential application for future cell or tissue
replacement therapy directly.
Development of culture conditions for mES cells
Culture condition towards serum free
ES cells had been cultured on mouse embryonic fibroblast
cells as a feeder of essential factor(s) for maintenance with
strictly tested and selected serum as a source of growth
factor supplement. In 1988, Smith et al. and Williams et al.
[44, 45] reported that one cytokine, LIF, could support ES
cell self-renewal without feeder cells, and showed that LIF
is the essential factor provided by feeder cells. Smith et al.
[46] further developed serum-free culture conditions with
BMP4 and LIF. mES cells are known to be prone to dif-
ferentiate into the neural cell lineage in serum-free media,
and what they showed is that inhibition of neural induction
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by BMP4 in addition to activation of STAT3 by LIF sig-
naling is sufficient to block differentiation and maintain
pluripotent self-renewal. Serum can be replaced by chem-
ically defined supplement, knockout serum replacement
(KSR from Life Technologies), and ES cells can be cul-
tured without feeder cells in the presence of LIF, but it is
not sufficient to propagate from single cell in this condi-
tion. Ogawa et al. [47] established adrenocorticotropic
hormone (ACTH), KSR and LIF conditions to grow at
clonal density.
In 2008, Qi-Long Ying et al. [35] established a novel
serum-free ES cell culture method that contains two kinase
inhibitors for GSK3 (CHIR99021) and Mek inhibition
(PD0325901) in the basal medium, so now it is simply
called 2i. This 2i condition firstly enabled us to culture ES
cells without LIF or its downstream signal transducer,
Stat3. In addition to its lack of necessity for LIF, this 2i
condition allows us to establish NOD mouse ES cell lines
[48, 49] and rat ES cell lines [50, 51], which were
impossible to establish before the discovery. In addition to
rat ES cells, the 2i condition allows us to establish rat EG
cells at the first time [52]. This condition allows us to
culture mES cells in a more homogeneous manner, which
is called ‘‘ground state’’ of mES cell.
ES cells cultured in serum and LIF
It is also well known that undifferentiated ES cells cultured
in conventional ES cell culture conditions such as serum
and LIF without feeders are very heterogeneous in terms of
gene expression and morphology. For example, Oct3/4
(also known as Pou5f1) is widely expressed in serum
containing culture conditions, but Rex1 (also known as
Zfp42) is not. Toyooka et al. [53] established a GFP knock-
in reporter ES cell line in Rex1 gene locus and showed that
Rex1-GFP-positive cells emerged from its negative frac-
tion and vice versa, but Rex1-negative cells did not con-
tribute to chimeras. From this observation, ES cells are
considered to fluctuate between partially differentiated and
undifferentiated status under serum and LIF conditions.
Genes such as Nanog, Dppa3, Klf4, Tbx3, and Esrrb are
also known to fluctuate in this culture condition [54–57].
What makes it possible to keep cells undifferentiated
in culture?
LIF signaling
Before the discovery of 2i culture, LIF was the sole mol-
ecule known to support self-renewal of mouse ES cells in
the presence of serum-derived factors, thus its downstream
signal and transcription factor network was extensively
examined for a few decades. LIF is a cytokine that belongs
to the interleukin 6 family and binds to LIF receptor to
make a heterodimer with gp130 (also known as Il6st). This
dimerization makes Janus Kinase (JAK) phosphorylate
gp130 and Stat3. Phosphorylated Stat3 trans-locates into
the nucleus where it works as a transcription factor in ES
cells [58]. gp130 is also known to activate Ras-Mapk signal
and PI3-Akt signal pathways in parallel to Stat3. Firstly,
Stat3 was shown to be a sufficient molecule to support LIF-
independent self-renewal [59]. Matsuda et al. constructed a
fusion protein that has a modified ligand binding domain of
the estrogen receptor combined at the c-terminal of Stat3,
called Stat3-ER. The localization of this fusion protein is
controlled by the addition of 4-hydroxytamoxifen (4-
OHT). They reported that the addition of 4-OHT in media
without LIF (this recruits the fusion protein into the
nucleus) is sufficient to support self-renewal. From this
observation, the Stat3 pathway is considered as the main
pathway activated by LIF.
Downstream of Stat3 target
By over-expressing the gene of interest in ES cells, we can
check their ability to support LIF-independent self-
renewal. Like forced nuclear localization of Stat3 sup-
porting LIF-independent self-renewal [59], Nanog, Esrrb,
Tbx3, Klf2, Klf4, Klf5, Gbx2, and Tfcp2l1 are also iden-
tified to be able to bypass LIF-Stat3 signaling [56, 60–67].
This showed that these transcription factors make a gene
regulatory network in parallel or downstream of Stat3. In
addition to these transcription factors, PI3 kinase and Akt
signaling activated by LIF and gp130 were also reported to
support self-renewal of mES cells [68, 69].
FGF-Mapk signal
Among the Fgf family molecules, Fgf4 is the main Fgf
produced by mES cells. Fgf4 starts to be expressed at
around 4–8-cell-stage embryo, and continues its expression
in the ICM of blastocyst and egg cylinder stages [70].
Genetically inactivated Fgf4-null embryos fail to implant
or produce pluripotent ICM outgrowth in vitro, so Fgf4 was
considered as a molecule that supports proliferation of
pluripotent cells in vivo and in vitro in an autocrine manner
[71]. To test this possibility, Fgf4 null ES cells have been
established, and found to have no effect in proliferation or
maintenance of the undifferentiated state [72]. Kunath et al.
[73] showed in 2007 that Fgf4 is essential for exit from
self-renewal to differentiate. They showed that Fgf4 null
ES cells can differentiate neither into neural nor mesoderm
lineages without the addition of Fgf4 into the media. Fgf
activates PI3 K in addition to Ras-Mapk pathways. They
also showed that Erk2 is the main downstream molecule
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that corresponds to this Fgf4 signaling by using Erk2 KO
ES cells.
Essential genes for keeping the specific gene regulatory
network in the mES cell
A number of genes have been identified that are highly or
specifically expressed in undifferentiated ES cells com-
pared to somatic cell lines or cancer cell lines, although
only a few genes have been reported to play an essential
role in the maintenance of undifferentiated mES cells
(Table 2). Oct3/4 is one such essential key player in
organizing the transcription factor network. On the other
hand, Sox2 is expressed in many other cell types and
cancer, however it makes heterodimer with Oct3/4 and
plays a crucial role in ES cells. These two genes are the
original half of the Yamanaka four-factor cocktail with
Klf4 and cMyc, which are sufficient for somatic cell
reprogramming [38]. In this section, I introduce some of
them on top of Oct3/4 and Sox2.
Oct3/4
Oct3/4 (also known as Pou5f1) was reported by two groups
independently, as Oct3 [74] and Oct4 [75], and so this
molecule is called Oct3/4 in this review. Oct3/4 is a
homeobox protein, and binds to octamer DNA motif. Oct3/
4 is expressed in pre-implantation-stage embryos and also
supplied as a maternal factor from oocytes. Oct3/4
knockout embryos fail to establish a pluripotent inner cell
mass at the blastocyst stage and die around implantation
[76], showing that it is required for early development.
Oct3/4 is proven to be essential for maintenance of in vitro
pluripotency by conditional knockout in ES cells [77].
ZHBTc4 ES cells do not harbor both endogenous Pou5f1
gene loci but are maintained undifferentiated by a tetra-
cycline (Tet) inducible Oct3/4 transgene. Tet addition into
the culture media results in a rapid loss of Oct3/4 protein
and differentiation into trophectoderm cells through de-
repressing the Cdx2 and Eomesodermin genes [78].
Sox2
Sox2 is a member of the high-mobility group of tran-
scription factors that consist of 21 genes. Different from
the expression pattern of Oct3/4, which is restricted to
pluripotent epiblast and germ cell lineages during early
development in mice, Sox2 expression is more broad in
the embryo, and it is also expressed in the trophectoderm
cell lineage in addition to epiblast [79]. Sox2 KO embryos
can implant but fail to propagate pluripotent epiblast,
resulting in lethality before gastrulation [80]. This
phenotype is different from Oct3/4. Sox2 KO ES cells are
established by using a similar approach to Oct3/4 [81].
Sox2 deletion also causes differentiation into trophecto-
derm-like cells but interestingly this Sox2 deletion mutant
ES cell phenotype was rescued by forced expression of
Oct3/4, indicating that its function overlaps. Actually, it is
now also known that Oct3/4 and Sox2 make hetero dimer
and co-bind to the same locus to maintain pluripotency
[82, 83]. Deletion of Oct3/4 cause the rapid down regu-
lation of known common target genes [58, 78], but Sox2
deletion needs more time to down-regulate these genes
[81], suggesting that Sox2 function is more supportive in
these common target sites.
Nanog
Another important molecule that is required for the
establishment of pluripotent cells is Nanog. Nanog was
identified most recently compared to other important
classic genes. Nanog, which belongs to a homeobox
protein group, was discovered by two independent
groups, and named after the mythological Celtic land of
ever young, ‘‘tir nan og’’ [60, 84]. Nanog expression
starts at the compacted morula stage, and then becomes
restricted to the ICM of the blastocyst, but is quickly
down-regulated at around the time of implantation [60].
Nanog is essential for establishment of in vivo pluripo-
tency [84] and also required for in vitro reprogramming
of differentiated cells [85], but is not required for main-
tenance of pluripotency in vitro [54].
Most of the transcription factors required for in vivo
epiblast formation are not required for in vitro
pluripotency
Oct3/4 and Sox2 are important molecules for the pluripo-
tency-associated gene regulatory network, but there are
several genes that play important roles in the establishment
of in vivo pluripotent epiblast cells but not essential for the
maintenance in vitro, such as Nanog. Also, there are sev-
eral genes that are thought to be important by gene over-
expression studies, but KO has no phenotype. These are
summarized in Table 2, and some of them are described
more in this text. Sall4 KO mice fail to develop after
implantation, although both ICM and TE cells appear intact
at the blastocyst stage. Sall4 null ICM has difficulty in
propagating in vitro to establish ES cell lines [86]. To
address the roles in the maintenance of gene networks in
ESCs, conditional KO was performed using a floxed allele,
and from this study, Sall4 was found not to be required for
the gene regulatory networks, but for repression of TE
differentiation through the direct interaction with histone
deacetylase (HDAC) [87].
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Prdm14 (PR domain containing 14) was identified as an
essential gene for establishment of the germ cell lineage in
mice [88]. It is reported in conventional ES cell culture
medium containing serum and LIF that Prdm14KO ES cells
cannot be established, but it is possible by using 2i culture.
Prdm14KO ES cells have an elevated level of Fgf signaling
pathway, so in the presence of Mek inhibitor, Prdm14 null
cells can be maintained. Prdm14 null cells also have an
Table 2 List of gene knockout/knockdown phenotypes in mouse and ES cells
KO mice phenotype (major phenotype 
 if more than one)
KO in ES cultured in 
serum and LIF
KO in ES cultured in 
2i and LIF
References
Oct3/4 (Pou5f1) Peri-implantation lethal No ICM out growth
Trophectoderm 
differentiation
No report [76, 77]
Sox2 Peri-implantation lethal No ICM out growth
Trophectoderm-like 
differentiation
No report [80, 81]
Nanog Peri-implantation lethal No ICM out growth
Unstable, but keep 
pluripotency
Maintain pluripotency [54, 60, 84]




Yolk sac, limb and 
mammary gland 
development
Differentiationa Maintain pluripotencya [94, 137, 138]




Placenta defect Mild differentiation
Differentiation in 2i 
without LIF
[64, 89]
Prdm14 Infertility Germ cell defect Differentiation Maintain pluripotency [88, 140, 141]
Foxd3 Peri-implantation lethal No ICM out growth
Differentiation into both 
extraembryonic and 
embryonic linage
No report [142, 143]
Nr0b1 (Dax1) Infertility Reproductive defect Differentiation No report [144, 145]
Klf2 Embryonic lethal Erythroid development No phenotype Maintain pluripotencya [94, 146, 147]
(E12.5-14.5)
Klf5 Peri-implantation lethal No ICM out growth Slow cell growth No report [62]
Gbx2 Embryonic lethal Brain development No phenotypea Maintain pluripotencya [65, 94, 148]
Tfcp2l1 Postnatal phenotype
Defects in duct 
development
Mild differentiationa Maintain pluripotencya [66, 67, 94, 149]
Stat3




No outgrowth in serum 
and LIF
Differentiation
Maintain pluripotency in 
2i
[35, 96, 150]
Rex1 (Zfp42) No obvious phenotype No phenotype No phenotypeb [151]
a Shows the phenotype of gene knock-down
b Unpublished observation from Austin Smith’s and Jennifer Nichols’ laboratories
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increased level of DNA methylation at the de novo meth-
ylation site by the up-regulation of DNA methyltransferase
(Dnmt) genes. Prdm14 protein physically interacts with
Jarid2 and Suz12, members of the Polycomb repressive
complex (PRC) 2, suggesting that the function of Prdm14 is
to recruit PRC2 complex into the promoter region that is
active in primed state epiblast cells including Dnmts.
Esrrb was recently reported as a downstream molecule of
LIF signaling [64] and Nanog [63], and Esrrb (-/-) ES cells
can be maintained in conventional culture [64]. However, in
2i culture, Esrrb (-/-) is essential for maintenance of pluri-
potency as an important GSK3 inhibition target, so it is
considered as an important molecule in the maintenance of
naı¨ve pluripotency. From KO study, the Esrrb gene is
apparently not required for epiblast development [89].
Single KO might be compensating for the other func-
tional overlapping factors. Some of the transcription factors
have other closely related family members, which are
expressed together. For example, in the developing
embryo, double KO of Gata1 and Gata2 [90], Klf2 and
Klf4 [91] cause more severe phenotypes in blood cell
development than single KO, or another example is Tead1
and Tead2 in notochord development [92]. In case of mES
cells, three members of Klf family genes such as Klf2,
Klf4, and Klf5 are expressed in undifferentiated state. Only
simultaneous knockdown of these three (not any of the
combination) shows the collapse of the network [93]. In
addition to the compensation by the family gene, there is a
genetic interaction between genes. To understand these
complexities, it is necessary to establish compound KO
cells. Recently, a computational modeling approach
revealed that combination of gene knockdown can be
predicted and some are sufficient to induce the network
collapse in ES cells [94].
Is this capturing in vivo pluripotency in vitro?
LIF-Stat3 signaling pathway
The question comes from the developmental biological
aspect: LIF signaling plays an important role in culturing
ES cells in vitro, but how does this signal work in vivo?
LIF is expressed in the blastocyst-stage embryo only in
trophectoderm cells, and its receptor Lifr and gp130 are
expressed in the ICM, detected by mRNA in situ hybrid-
ization [95]. Although it is expressed, it was unclear if this
signal is active in this stage of embryo. Immunostaining of
phospho-Stat3 suggests that at least the signal is active in
ICM cells [96], but Stat3 KO embryos survive over
implantation, and die around E6-7 [97]. Lif, Lifr, and gp130
KO embryos are known to develop normally until around
mid-gestation. Lif KO mice are born, but with female
infertility because blastocysts are unable to implant in Lif
(-/-) uteri [98]. Lifr KO mice have a perinatal lethality with
a defect in motor neuron development [99, 100]. gp130 KO
mice die around E12.5-16.5 due to cardiac and hemato-
poietic defects [101]. From these, the LIF signal was
thought not to be essential for the establishment of plu-
ripotent epiblast cells.
Embryonic diapause is a phenomenon observed in some
mammals to keep the embryo un-implanted in the uterus
during lactation [102]. Interestingly, ES cells were first
established from embryos in diapause [21]. New insight
came after the analysis of Lifr and gp130 mutant embryos
in a diapause [103]. Lifr and gp130 compound heterozy-
gotes were intercrossed to generate double-mutant
embryos, and pregnant mothers were ovariectomized to
induce diapause. After a certain period of diapause,
embryos lacking both gp130 and Lifr transferred into
pseudopregnant females could not be recovered. gp130 KO
embryos in diapause showed no surviving epiblast cells and
culture outgrowth from gp130 (-/-) embryo yielded only
extraembryonic endoderm cells. Recently, maternal/zygo-
tic Stat3 null embryos have been analyzed, and revealed its
requirement for the maintenance of pluripotent ICM cells
during implantation [96]. These results strongly support the
idea that Stat3 activation by LIF or other stimuli is required
to keep the pluripotent ICM in vivo as well as in vitro.
Two kinases inhibition in vivo
How about the 2i cultured cells? 2i medium consists of
inhibitors of two protein kinase: Mek and GSK3. ES cells
can be propagated without LIF in this condition. Mek is a
component of FGF-Mapk signaling and GSK3 is a com-
ponent of the beta-catenin destruction complex, which is
involved in the canonical Wnt signaling pathway. Here I
try to uncover one by one.
Mek inhibition
Among the 22 Fgf ligands and four receptors [104], only
Fgf4 and Fgfr2 disruption resulted in pre-implantation
lethality [71, 105]. As described above, Fgf4 is produced
by undifferentiated ES cells, but is not required for either
the maintenance or growth of pluripotent cells in vitro [72].
Rather it is required for differentiation [73]. How does this
signal work in the embryo? Single-cell gene expression
analysis at E3.5 revealed that Fgf4 is expressed in the
Nanog-positive epiblast lineage and its receptor Fgfr2 is
expressed in Gata6-positive primitive endoderm cells
[106]. The effect of Fgf inhibition during pre-implantation
development was examined by adding these inhibitors in
the culture medium from different time points of devel-
opment [107]. When eight-cell-stage embryos are cultured
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with these inhibitors or Mek inhibitor alone for 2 days, the
primitive endoderm lineage marked by the expression of
Gata4 protein is almost completely blocked and every ICM
cell expresses Nanog. Injecting these ICM cells into
another blastocyst revealed that these cells possess pluri-
potency. However, if the two inhibitors are added after
blastocyst formation, at E3.75 then the embryos cultured
for 2 days, embryonic development, and lineage segrega-
tion are not affected.
Yamanaka et al. [1] performed the opposite experiment
for analyzing Fgf function in primitive endoderm forma-
tion. When 2–4-cell-stage embryos (E1.5) were treated
with a very high concentration of Fgf4 with heparin, this
resulted in the conversion of ICM cells into Gata6-positive
primitive endoderm cells at the expense of Nanog-positive
epiblast lineage cells. From these observations, Mek inhi-
bition suppresses PrEn and enhances lineage commitment
of ICM cells towards epiblast lineage.
GSK-3 inhibition
GSK-3 is a serine/threonine kinase that is widely expressed
and consists of two different gene products, GSK-3a and
GSK-3b [108–110]. GSK-3a and GSK-3b have a highly
conserved kinase domain, so most of the inhibitors affect
both of them together [111]. One of the functions of GSK-3
is to interact with scaffolding protein Axin and Ade-
nomatous polyposis coli (APC) to make b-catenin
destruction complex. This complex phosphorylates the
N-terminus of b-catenin, and phosphorylated b-catenin is
then ubiquitinated, followed by degradation with protea-
some. When Wnt ligands bind to its receptor Frizzled and
Lrp5/6, GSK-3 does not phosphorylate b-catenin, resulting
in escape from proteasome-mediated degradation. This b-
catenin translocates into the nucleus and binds to Tcf3
[112]. Tcf3 belongs to the repression type of transcription
factors, and b-catenin binding abrogates the repressor
function of Tcf3 to continue to express pluripotency-
associated genes. Consistent with this, Tcf3 KO ES cells
show pronounced delay to exit from pluripotency [113,
114]. KO embryos show delayed shut down of pluripotency
genes during gastrulation, and inhibit mesodermal gene
expression [115].
Recombinant Wnt3a added to culture media is reported
to enhance the self-renewing activity of mES cells [116,
117], but the importance of the Wnt signal in the in vivo
blastocyst-stage embryo is not well characterized because
there is no evidence for Wnt function in blastocyst-stage
embryo by KO studies. Axin2 is the direct target of
canonical Wnt signaling pathway, so this gene is used as a
marker to visualize active Wnt signals [118]. Pre-implan-
tation-stage embryos express the Axin2-LacZ reporter only
in the ICM regions and its expression diminishes after
implantation [119]. The Wnt signal might be active in the
developing and proliferating naı¨ve pluripotent cell, but this
signal itself is not necessary for establishment and main-
tenance of the pluripotent state in vivo, shown by Porcn
KO embryo [120]. From these observations, it is unclear
that the Wnt signal plays a role in enhancing the pluripo-
tent state in vivo, and it is necessary to analyze these KO
embryos in diapause to conclude in future.
Gene expression comparison between ES cells and ICM
cells
Recent technology revealed the gene expression profile
from small amounts of cells, and even from a single cell
[106, 121] of peri-implantation-stage embryo. Tang et al.
compared gene expression profiles during the process of
ICM outgrowth to ES cells. They showed the difference
between E3.5 ICM and ES cells cultured in serum and LIF.
Most recently, Boroviak et al. [122] examined the gene
expression profile from the pre-implantation-stage to post-
implantation-stage epiblast and compared gene expression
with cells cultured in 2i or 2i and LIF. According to the
gene expression profile by Boroviak et al., naı¨ve ES cells
are most similar to the epiblast cells at E4.5 after primitive
endoderm cells are segregated. They also showed efficient
establishment of ES cell lines from E4.5 epiblast.
Is EpiSC relevant to post-implantation epiblast?
EpiSC are stem cells that can be established from a broad
range of developmental stages from E5.5 to E8.0. It is
important to culture the cells expressing Oct3/4 to establish
the stem cell line [123]. Although their origins vary, the
cells in culture have very similar gene expression profiles,
and the expression of lineage marker genes, for example T
or Sox17, are heterogeneous. Global gene expression pat-
tern analysis shows that EpiSC lines in culture are most
similar to the anterior primitive streak cells in the gastru-
lation-stage embryo [124]. Basic features of EpiSC are
conserved between lines, but they are variable between labs
because the culture condition is slightly different. Essential
components to support their self-renewal are activin and
Fgf signal. Some labs used feeder cells and bFgf only
relying on activin production by feeders and endogenous
Nodal, but others used serum or KSR in addition to activin
A and bFgf. Recent findings by two independent groups
suggest the model by which we can maintain the EpiS cell
in a more pure state. They used the addition of Wnt signal
inhibitor XAV939 [125, 126]. This is a reasonable com-
ponent because Wnt signal in the post-implantation embryo
enhances mesoderm and endoderm formation and hetero-
geneity observed in the culture are spontaneous differen-
tiation of T or Sox17-positive cells.
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Conclusions
Since the establishment of mES cells as a genuine plurip-
otent stem cell, the secrets behind it have been uncovered
one by one. Especially, after the discovery of LIF as an
essential external signal, the analysis of the gene regulatory
network downstream of this signal is intensively pro-
gressed and key transcription factors have been identified.
After the discovery of 2i culture, we can keep the mES
cells in the homogeneous manner as a ground state. This
means we have been able to overcome the differences
potentially existing in the different laboratories to further
investigate properties of the naı¨ve state in vitro. Gene
expression analysis by Boroviak et al. [122] supports the
idea that this ground state is not an artifact but rather it is
captured in vivo pluripotent cell in vitro.
On the other hand, we have not found a core gene
regulatory network of primed cells yet. EpiSCs can be a
very good tool to analyze different states of pluripotency,
which might be governed by different sets of pluripotency
gene regulatory networks with lineage marker genes like
Otx2 [127, 128] or Eomesodermin [129]. It is unclear why
these cell lines lose germ line competency [42]. Interest-
ingly, except for mice and rats, it is very difficult to
establish naı¨ve pluripotent stem cells in other mammals.
The developing human embryo has a slightly different
morphological feature compared with mice at the late
blastocyst stage. In human, ICM cells at late blastocyst
stage make a single layer of epiblast cells overlying the
extraembryonic layer before implantation, on the other
hand, the mouse epiblast at this stage is a three-dimen-
sional aggregate under the extraembryonic endoderm layer.
This evokes the speculation that the human embryonic
stem cell is more natural and stable in the primed than
naı¨ve state, which might exist only at the early blastocyst
stage in a small time window in human. In addition to this
thought (i.e., naı¨ve or primed), so far, it seems to be very
difficult to establish non-human primate chimeric animals
by injecting cultured pluripotent stem cells. The reason for
this difficulty is not clear yet, however the fact that EpiSC
can make chimeras only when injected into post-implan-
tation epiblast suggests that we need to capture the proper
naı¨ve state from those animals.
Compared to human, in mice, we now understand well
what kind of cell identity it has and how similar mES cells
are to their in vivo counterparts, so it is time to analyze how
to start to differentiate. We know ES cells can differentiate,
but little is known how. Recently, some reports tried to
identify new molecules that are required for the exit from
the ground state [130–132]. Mouse ES cells have a longer
history than human, however knowledge about human ES
cell are rapidly accumulated. Recently, human ES cells that
have a similar gene expression signature to mouse naı¨ve
state have been reported [133, 134]. From these reports, we
are starting to open the gate for proper human naı¨ve cells. In
conclusion, I optimistically speculate in the near future that
we can manage to capture and control the undifferentiated
state and differentiation of various types of pluripotent stem
cells (which might be reflecting different stages of embry-
onic development) from various animals in vitro.
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